dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· March 26, 2026

This Tech Giant Is Buying Back Stock Hand Over Fist. Insiders Are Buying, Too. Should You Follow?

View original at nasdaq.com
“Last year, Salesforce generated $14.4 billion of free cash flow, and it expects to grow that figure by 10% in fiscal 2027.”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Salesforce was not included in the 10 best stocks for investors to buy now

    60% confidence

  • If Salesforce's internal data and sales professionals can help customers use tokens more effectively in a proprietary way, that could be a recipe for generating value

    60% confidence

  • Salesforce expects to grow free cash flow by 10% in fiscal 2027

    60% confidence

  • It may take several quarterly earnings reports or updates to convince skeptics that the AI fears are overblown

    60% confidence

  • Salesforce will be able to harness AI to its advantage rather than be disrupted by it

    60% confidence

  • If signs emerge that Salesforce's platform will be one of the AI survivors or beneficiaries, it could be one of the best buys in the market

    60% confidence

  • AI fears over software disruption may be overblown, though confirmation will take years

    60% confidence

Data points we hold from this source

Salesforce · price to fcf9.5 ratio
Salesforce · net debt30 USD
Salesforce · shares outstanding810 millions
Salesforce · shares retired103 millions
Salesforce · share count reduction11.1 percent
Salesforce · shares outstanding923 millions
Salesforce · net debt5 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,997
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,997 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
This Tech Giant Is Buying Back Stock Hand Over Fist. Insiders Are Buying, Too. Should You Follow?: Source | Via News | fr.via.news